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creativecommons.org/licenses/by-nc-Summary Looking at the worldwide emergency of antimicrobial resistance, international trav-
ellers appear to have a central role in spreading the bacteria across the globe. Travellers’ diar-
rhoea (TD) is the most common disease encountered by visitors to the (sub)tropics. Both TD and
its treatment with antibiotics have proved significant independent risk factors of colonization by
resistant intestinal bacteria while travelling. Travellers should therefore be given preventive
advice regarding TD and cautioned about taking antibiotics: mild or moderate TD does not
require antibiotics. Logical alternatives are medications with effects on gastrointestinal func-
tion, such as loperamide. The present review explores literature on loperamide in treating TD.
Adhering to manufacturer’s dosage recommendations, loperamide offers a safe and effective
alternative for relieving mild and moderate symptoms. Moreover, loperamide taken singly does
no predispose to contracting MDR bacteria. Most importantly, we found no proof that would show
antibiotics to be significantly more effective than loperamide in treating mild/moderate TD.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
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Travellers’ diarrhoea (TD) remains the most common
medical problem encountered by travellers. WHO defines
TD as three or more loose or liquid stools per day, or more
frequently than is normal for the individual [1]. Although
rarely severe and almost always spontaneously resolving
[2e5], TD incurs significant morbidity and causes inconve-
nience to a high number of individuals: of all travellers to
the (sub)tropics [6], 40e60% are expected to contract TD
[2e4,7]. The inconvenience may not remain short-term:
recent studies suggest that 3.0e13.6% of travellers with
TD develop post-infectious irritable bowel syndrome (IBS)
[8e13].
Antimicrobials have for decades been considered the
primary option in treatment [14] e and even prevention
[15e17] e of TD. One justification for this approach has
been its presumed potential to prevent postinfectious IBS.
However, we did not find any investigations that would
have shown antibiotic treatment of TD to prevent IBS. On
the contrary, one study suggests that taking antimicrobials
actually increases the risk of post-travel IBS [9]. The in-
crease of antimicrobial resistance raises serious concern
over excessive antibiotic use [18e20]. The use of antibi-
otics for TD adds to this problem, as the drugs predispose
travellers to contracting multidrug-resistant (MDR) bacteria
which they may eventually spread to their home countries
[21e23]. Besides global health care, antibiotics may harm
individuals, not only by increasing the risk of infections by
MDR bacteria, but by causing long-lasting changes in the
intestinal microbiota [24]. Therefore, many current guide-
lines do not encourage treating TD with antibiotics [25]. In
recent research, however, fairly little attention has been
paid to non-antibiotic drugs with effects on the gastroin-
testinal function. These include loperamide, diphenoxylate
plus atropine, and rasecondrontil, drugs of which loper-
amide has been available for decades, whereas race-
cadotril, despite its indication for acute diarrhoea [26], has
so far not been studied among travellers. In a recent study,
loperamide taken singly did no predispose to contracting
MDR bacteria [27].
In this review we discuss the effectiveness and safety of
loperamide in treating TD.
1.1. Loperamide e pharmacological aspects
Loperamide is an oral opioid-like agent which is considered
nonabsorbable: only insignificant amounts reach the sys-
temic circulation and even less penetrate the blood-brain
barrier [28]. Therefore, at recommended dosages, the drug
lacks central opioid-like effects, including centrally medi-
ated blockade of intestinal propulsion [29]. In the intestine,
it has an antisecretory effect mediated via m-opioid re-
ceptors and non-opioid-receptor mechanisms. At higher
dosages, however, loperamide also decreases motility, an
effect mediated via m-opioid receptors in the myenteric
plexa of the bowel. Both of these mechanisms may be
covered by dosage recommendations: low doses exploit the
antisecretory and higher ones the antimotility effect [30].
Loperamide undergoes first-pass metabolism by CYP3A4 and
CYP2C8 [31], a point of potential relevance whenconcomitantly using medicines metabolized through the
same enzyme systems.
Loperamide is currently marketed in 110 countries. The
recommended regimen is a 4-mg loading dose followed by
2 mg after every episode of diarrhoea. Some manufactures
recommend that in acute disease the maximum dose would
be 12 mg/day and the drug should not be used for longer
than 48 h [32], while others allow 16 mg and even five-day-
use [33].
1.2. Effects of various pathogens on bowel
functions
The total fluid turnover of the intestine is about eight litres
per day, most of which will be re-absorbed. The various
intestinal pathogens may disturb the normal intestinal
functions in differing ways as described below.
Many intestinal pathogens, with enterotoxinogenic
Escherichia coli (ETEC) and Vibrio cholerae as two well-
known examples, produce enterotoxins which stimulate
the active water transport mechanisms of the enterocytes
via ATP-dependant sodium/potassium pumps (secretory
diarrhoea) [34]. As obvious, the antisecretory effect of
loperamide is especially advantageous in this setting.
The main pathogenetic mechanism of some other path-
ogens, such as Campylobacter spp. and Salmonella spp., is
not enterotoxin-mediated but, instead, the invasive nature
of the bacteria determines the clinical picture: the bacteria
invading the mucous membrane cause inflammation and
ulcerations [35]. Blood and plasma leaking into the lumen
draw even more fluid from the systemic circulation through
osmosis. In addition, the widespread apoptosis of enter-
ocytes leads to a decrease in the total resorptive ability of
the bowel. Loperamide appears to have some effect even in
this setting [36], probably by diminishing fluid secretion
from the remaining viable enterocytes. Loperamide has
been suggested to be harmful in infections with invasive
pathogens: through its antimotility effect it may prevent
the natural mechanism where pathogens are washed out.
Accordingly, the drug is not recommended for cases with
high fever or overtly bloody diarrhoea [14,25,32,33].
In cases with Clostridium difficile as a potential path-
ogen, loperamide and all other agents decreasing intestinal
motility should be avoided, at least initially. If the diagnosis
is confirmed, administering loperamide in conjunction with
antibiotics effective against C. difficile is probably safe
[37], although many experts advise against it [38e42]. Most
importantly: when C. difficile is suspected, loperamide
should not be used without an effective anti-clostridial
agent [37].
2. Methods
2.1. Loperamide and travel e systematic search for
studies
PubMed search with terms “loperamide” and “travel”
yielded 86 articles, 71 of which were in English. From them
we excluded five letters and 34 reviews on a subject other
than loperamide; one case report did not focus on
Systematic review of loperamide 301loperamide, and in two it was not administered to travel-
lers. Finally, a total of 29 articles were included in this
review (Fig. 1, Tables 1e3).
2.2. Search for case reports on serious adverse
events
Since no serious adverse events were reported in the arti-
cles we found applying the criteria above, we ran a further
search in PubMed using the terms loperamide and
“adverse”, “death”, “fatal”, “megacolon”, “ileus”,
“necrotising colitis”, OR “perforation”. This search was not
restricted to travellers. In addition, we reviewed the au-
thors’ archives. Finally, 24 case reports altogether were
included (Table 4).
3. Results
3.1. Effectiveness of loperamide in travellers’
diarrhoea: randomized trials
Of the 15 randomized trials conducted among travellers,
four were carried out with US military personnel, one with
both military and tourists, and the remaining 11 with stu-
dents or ordinary tourists. There were nine investigations
with Mexico as the destination which included 59% of allRecords identified by Medline
search with terms
“loperamide” and “travel”
(n = 86 )
- not w
- letters
Full-text articles assessed for 
eligibility
(n = 66)
- reviews
- case rep
- loperam
Records in systematic review
(n = 29)
- randomized studies (n = 15)
- nonrandomized studies (n = 13)
- systematic review and meta-
analysis of loperamide combined 
with antibiotics (n = 1)
Figure 1 Flow diagram illustrating the article search of our sy
effects of loperamide were collected in authors’ archives and in th
“death”, “fatal”, “megacolon”, “ileus”, “necrotising colitis”, OR “
ellers; a total of 24 reports were included.research subjects. The results of these studies are sum-
marized in Table 1.
In 2008, Riddle et al. [43] published a review and meta-
analysis of loperamide as an adjunct to antibiotic treat-
ment for TD. The combination was found more effective
than antibiotics alone in five studies [44,45,48,51,52]; one
of them reported, however, that the effect had seemed to
wane by the fourth day [52]. In one study, adding loper-
amide had not shortened the illness despite reducing bowel
movements [47]. In the meta-analysis, the difference be-
tween the combination and antibiotics alone groups proved
no longer significant after the second day of treatment: the
authors attributed this to the benign course of the disease,
speculating that those with ongoing symptoms even on the
third day had probably been infected with an invasive
pathogen. It is also noteworthy that loperamide had been
taken for two days only. The authors concluded that
loperamide can be used even in invasive disease, yet
further studies would be needed. The use of loperamide as
single treatment for less severe disease was also discussed,
and adding antibiotics was recommended against symptoms
that do not resolve within 12 h.
We only found two RCTs [44,52] comparing antibiotics to
loperamide taken alone in treating TD. Ericsson et al. [44]
reported loperamide to be equal to cotrimoxazole.
DuPont et al. [52] found rifaximin to be more effective than
loperamide in reducing the TLUS (time from administrationExcluded records:
ritten in English (n = 15)
 (n = 5)
Excluded records:
 with focus other than loperamide (n = 34) 
orts on drugs other than loperamide (n = 1)
ide not administered to travellers (n = 2)
stematic review. In addition, case reports on serious adverse
e PubMed with the terms: “loperamide” and “adverse effect”,
perforation”. The search for cases was not restricted to trav-
Table 1 The results of a systematic review on loperamide for TD among travelers: randomized studies.
First author,
year
Destination
of travel
Type
of study
Population Patients in
entire study
Study
subjects
with TD
Serious
adverse
events
Loperamide
max dose
Medications
used/compared
Safety: LO against
recommendations
Effectiveness
Randomized trials
Studies included in Riddle et al meta-analysis
Riddle (meta-
analysis
2008) [43]
Various
destinations
Meta-
analysis of
randomized
controlled
trials
Travellers
and US
military
1435 1435 No SAE* 16 mg -Proportion of invasive
pathogens:
11% Shigella,
11% Campylobacter
4% Salmonella
AB þ LO > AB
Ericsson 1990
[44]
Mexico RCT Student
travellers
227 227 No SAE* 16 mg LO 41%
TMP-SMX vs LO
alone vs
combination
9/93 bloody stools
2 cases with Campylobacter
AB þ LO >
LO Z AB
Taylor 1991
[45]
Egypt RCT US military
personnel
104 104 No SAE 16 mg LO: 48%
(CIPþ/ LO)
Exclusion criteria:Bloody
stools or high fever
AB þ LO Z AB
Ericsson1992
[46]
Mexico RCT Student
travellers
190 190 No SAE 16 mg LO: 100%
TMP-SMX
(dosing)þLO
Exclusion criteria: Bloody
stools or high fever 10 cases
with Shigella
All used LO
Petruccelli
1992 [47]
Thailand RCT US military
personnel
142 142 NR 16 mg LO: 65%
(CIP þ/ LO)
Exclusion criteria: Bloody
stools, high fever or TD > 4
days
37% microscopic blood in
stools
41% Campylobacter
18% Salmonella
4% Shigella
No differences
in duration of
illness
(but fewer bowel
movements)
Ericsson 1997
[48]
Mexico RCT Student
travellers
166 166 No SAE 16 mg LO: 33%
OFL þ/LO
12/54 fever in LO-group
5 Shigella in LO group.
AB þ LO > AB
Ericsson 2001
[49]
Mexico RCT Student
travellers
88 88 No SAE 16 mg OFL þ LO 100% Bloody stools or high fever
exclusion criteria
10% developed fever
All used LO
Sanders, 2007
[50]
Turkey RCT US military
personnel
207 207 No SAE 16 mg LO 100%
Azithro þ LO vs
levo þ LO
Exclusion criteria: Bloody
stools or high fever
7% Campylobacter
All used LO
Ericsson, 2007
[51]
Mexico RCT Student
travellers
176 276 No SAE* 16 mg LO: 34%
(Azithroþ/LO)
11/59 (59 used LO) bloody
stools, no fever
AB þ LO > AB
DuPont, 2007
[52]
Mexico RCT Student
travellers
310 310 No SAE,* Max.
8 mg/day
for 2 days
LO 34%
RIF þ LO 34%
RIF 33%
Exclusion criterion: Bloody
stools Fever not reported
4 cases with Shigella in LO
groups
Day1:AB þ LO >
AB Z LO
Day4:AB þ LO Z
AB > LO
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Studies not included in Riddle’s meta-analysis
Johnson 1986
[53]
Latin
America
Randomised
nonblinded
trial
Travellers 219 219 No SAE* 16 mg LO 51%
Bismuth
salicylate 49%
Exclusion criteria: Bloody
stools or high fever
12 of the users of lo had
shigella
LO > bismuth
salicylate
duPont 1990
[54]
Mexico RCT Student
travellers
203-> 180
eligible for
analyses
180 No SAE* 8 mg LO 45%
Bismuth
salicylate 55%
(LO vs bismuth)
Exclusion criteria: Bloody
stools, high fever or TD
requiring AB
LO > Bismuth
salicylate
Okhuysen
1995 [55]
Mexico RCT Student
travellers
173 173 No SAE* 16 mg LO 34%
Zaldaride 33%
Placebo 33%
Exclusion criteria: Bloody
stools or high fever
Shigella 9%, salmonella 2%
LO > Zaldaride Z
placebo
Silberschmidt
1995 [56]
Egypt RCT Travellers 436 TD; 331
original
analysis
331 No SAE* 16 mg LO 27%
Zaldaride 56%
Placebo 17%
Exclusion criteria: Bloody
stools
Salmonella 2%, Shigella 1%
Zaldaride Z LO >
placebo
Caeiro 1999
[57]
Mexico Randomised
nonblinded
trial
Travellers 80 80 No SAE* 8 mg LO 100%
ORT 50%
Not reported ORT did not
add efficacy
Letizia, 2014
[58]
Turkey Randomised
nonblinded
trial
US military
personnel
109 109 No SAE* NR LO 69%
AB 19%
Not reported. Pre-deployment
provision of
LO did not
diminish the
use of AB.
AB use 15/62
RCT Z randomized controlled trial.
LO Z loperamide.
CIP Z ciprofloxacin.
RIF Z rifaximin.
OFL Z ofloxacin.
TMP-SMX Z cotrimoxazole.
TD Z travellers’ diarrhoea.
AB Z antibiotic.
SAE Z serious adverse event.
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Table 2 The results of a systematic review on loperamide for TD among travellers: nonrandomized studies.
First author,
year
Destination
of travel
Type of study Population Patients in entire
study
Study
subjects
with TD
Serious
adverse
events
Loperamide
max dose
Medications
used/compared
Safety: LO against
recommendations
Effectiveness
Prospective studies
Hill 2000
[59]
Various
destinations
Prospective
questionnaire
Travellers 784; 270 had TD
and 88 “loose
motions”
358 NR NR antimotility agent
(mainly LO) or
bismuth
salicylate alone: 43%
AB: alone 11%
antimotility/
bismuth þ
AB 22%
22% fever
1.5% blood in stools
No difference in
subjective
effectiveness
between
antimotility/
bismuth, AB or
combination
Peetermans
2001 [60]
Various
destinations
Prospective
questionnaire
Travellers 84; 43 (51%) TD 43 NR NR LO 79%
AB 5%
3/43 bloody stools
3/43 high fever
Not reported
Pitzurra
2010 [3]
Various
destinations
Prospective
questionnaire
Travellers 2800; all
diarrhoea 1265
1265 NR NR LO 58%
AB 5%
166 bloody stools; of
these AB: 21%, LO
alone: 23%
Not reported
Porter 2010
[61]
Turkey Prospective
questionnaire
US
military
202 202 NR NR LO 87%
AB 100%
8% bloody stools, 34%
fever
Not reported
Soonawala
2011 [2]
Various
destinations
Prospective
questionnaire
Travellers 390; 160 TD 160 NR NR LO 33%
AB 9%
Not reported Not reported
Belderok
2011 [4]
Various
destinations
Prospective
questionnaire
Travellers 1202/781 subjects
with TD
781 NR NR AB 5%
antimotility
such as
loperamide 30%
14% fever
4% bloody stools
Not reported
Lalani 2015
[12]
Various
destinations
Prospective
questionnaire
US
military
personnel
1120; 270 had TD
(24%)
270 NR NR AB 30%
LO not reported
23% had febrile
diarrhoea or bloody
stools
AB did not
shorten the
course of disease
Kantele
2016 [27]
Various
destinations
Prospective
questionnaire
Travellers 288 288 No SAE
(unpublished
data)
NR LO alone 31%
LO þ AB: 5%
Unpublished data: 15%
of LO users had fever
>37.5
Not reported
Retrospective studies
Meuris 1995
[62]
North Africa Retrospective
questionnaire
Travellers adults 5373
(2000 Z 37.2 TD)
children 818
(225 Z 27.5% TD)
2225 (225
children!)
NR No SAE* 43% LO
11% AB þ LO
22% took LO for severe
TD
þ29% LO þ AB
LO > AB Z no
treatment, but
AB treatment
was nifuroxazide
Reinthaler
2004 [63]
Various
destinations
Retrospective
questionnaire
Travellers 434 with TD 434 NR NR LO 40%
AB 29%
Not reported Not reported
Sanders
2005 [64]
Egypt Retrospective
questionnaire
Us military 129 with TD 129 NR NR LO 13%
LO þ AB 83%
25% fever
2% bloody stools
7 Campylobacter, 2
Shigella
96% used LO
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Systematic review of loperamide 305of first dose until passage of last unformed stool), yet the
mean number of unformed stools was lower in the loper-
amide group the first day of treatment. On day five, no
significant differences remained. It should be noted that
the subjects in the loperamide group only took the medi-
cine for two days, while those in the rifaximin group
continued treatment for three.
Loperamide proved more effective than bismuth salicy-
late in one RCT [54] and in one randomized nonblinded trial
[53]. In other studies, loperamide was found more effective
than zalaride maleate and placebo [55], or equal to zalar-
ide maleate, but more effective than placebo [56].
In another investigation, oral rehydration therapy did
not prove to add effectiveness to loperamide taken singly
[57]. Furthermore, in a study exploring pre-deployment
provision of loperamide the need for antibiotics was not
decreased [58].
In the majority of randomized studies, patients with high
fever and bloody stools had been excluded before
randomization. However, invasive pathogens were detec-
ted in many cases. No serious adverse events were reported
(Table 3).
3.2. Effectiveness of loperamide in travellers’
diarrhoea: nonrandomized studies
The nonrandomized studies comprised seven prospective
and five retrospective questionnaire-based studies (Table
2); the number of subjects with TD varied between 43
and 8096. In none of the observational studies reporting
outcomes were antibiotics found superior to loperamide
taken singly [12,59,62,66]. The duration of post-treatment
diarrhoea was similar among 1259 US military personnel
regardless of whether they had used loperamide or antibi-
otics alone or together as combination therapy [66]. Hill
et al. [59] found no differences in subjective effectiveness
between antimotility agent (mostly loperamide) and bis-
muth salicylate, and antibiotics and their combination
among 358 travellers with TD or “loose motions”, not even
in the moderate/severe groups. Loperamide taken singly
was proved superior to nifuroxazide in an investigation
carried out by Meuris et al. [62] with travellers to North
Africa.
3.3. Serious adverse events in randomized/
nonrandomized studies reporting use of
loperamide for TD
None of the questionnaire-based studies reported serious
adverse events (either did not report adverse events at all
or they were not severe) (Table 3). Some of these in-
vestigations included a substantial proportion of travellers
with severe TD and even dysentery, but only a few studies
where loperamide was taken singly presented data on the
proportion of those with severe TD/dysentery: Pitzurra
et al. [3] explored 1265 volunteers with TD, and found that
out of the 166 travellers with dysentery, 38 (23%) had used
nothing but loperamide. Likewise, in an earlier investiga-
tion [62], 22% of the subjects had only taken loperamide
for severe TD, yet no serious adverse events were
reported.
Table 3 Studies that report any adverse effects.
First author, year Adverse effects in LO group Adverse effects in
placebo group
Adverse effects in groups
with other treatments
Johnson 1986 [53] 8 cases with constipation (7.2%) No placebo group Bismuth subsalicylate: 1
case with constipation (0.9%)
duPont 1990 [54] Unspecified minimal
adverse effects
(proportion not reported)
No placebo arm Bismuth subsalicylate:
unspecified minimal adverse
effects (proportion not reported)
Ericsson 1990 [44] NR NR 1 case of rash with TMP-SMX
Okhuysen 1995 [55] 31% unspecified
adverse effect
17% unspecified
adverse effect
Zaldaride maleate: Unspecified
adverse effect 22%
Silberschmidt 1995 [56] 13% unspecified
adverse effect
15% unspecified
adverse effect
11e15% unspecified adverse
effect with zaldaride maleate
Meuris 1995 [63] Constipation 2.4% No placebo group Those who took nifuroxazide
took also LO
Caeiro 1999 [57] 10% unspecified minor
adverse effects
No placebo group 15% unspecified minor
adverse effects
DuPont, 2007 [52] Any adverse effect: 74%,
Constipation: 7%
Nausea 22%
Vomiting: 12% (significant
difference vs. RIF alone)
Abdominal cramps 33%
(significant difference
vs. LO þ RIF)
(RIF alone)
Any adverse event: 69%
Constipation:5%
Nausea: 11%
Vomiting: 3%
Abdominal cramps 23%
(RIF þ LO)
Any adverse event: 64%
Constipation: 8%
Nausea: 18%
Vomiting 4%
Abdominal cramps: 13%
Ericsson, 2007 [51] 1/56 rash, 4/56 headache No placebo group All received azithromycin;
Azithromycin alone: 1/106
rash, 7/106 headache,
1/106 dizziness
Letizia, 2014 [58] 1 case with constipation (2.1%) No placebo group 6 cases with constipation
in the nonloperamide group (9.8%)
LO Z loperamide.
RIF Z rifaximin.
TMP-SMX Z cotrimoxazole.
TD Z travellers’ diarrhoea.
AB Z antibiotic.
SAE Z serious adverse event.
306 T. La¨a¨veri et al.To sum up, in all of the randomized or nonrandomized
studies found applying the search criteria set for this review
(Tables 1e3), only mild adverse effects were detected. This
prompted us to run yet another search in PubMed on
possible case reports (see below) and include, besides TD,
also other indications for taking the drug.
3.4. Case reports on serious adverse events with
loperamide
Searching further, twenty-four case reports (Table 4) were
discovered to include a suspicion of serious, in some cases
fatal, complications in patients having used loperamide.
There were seven cases with severe cardiac arrhythmias
[86e88] and two cases leading to death [77,85] where the
patients had taken an overdose of loperamide ranging from
70 mg to almost 800 mg. Two cases with anaphylaxis were
reported [76,78], one of them fatal. In another fatal case
loperamide had been administered to a patient taking
clozapine during an outbreak of diarrhoea, and the additive
anticholinergic effect was speculated to have contributedto toxic megacolon [74]. Two cases with necrotising
enterocolitis [69] and two with paralytic ileus [68] con-
cerned infants treated with loperamide; one was a clear
misuse (1.4 mg/kg administered to a 17-month-old baby).
In two case reports with toxic megacolon, loperamide
had been used for diarrhoea when treating patients previ-
ously given broad-spectrum antibiotics [70,79]; C. difficile
was eventually identified as the causative pathogen.
Five case reports described acute pancreatitis
[72,81,83,89,90]. One was recurrent: both episodes had
been preceded by use of loperamide with normal dosage
(6 mg). Two patients had taken an overdose of loperamide
[72,81].
With the exception of the cases of anaphylaxis [76,78]
and catatonia [84], there were seven which could be
attributed to TD-like conditions. In two cases (toxic meg-
acolon with Campylobacter and bacteraemia caused by
Shigella), loperamide was used by a patient with bloody
stools [73,82]. In addition, there were four cases with
necrotising enterocolitis (three with perforation), in which
loperamide had been taken for three days by three patients
Table 4 Case reports on serious adverse events with users of loperamide.
First author, year Serious adverse
event diagnosis
Serious adverse event description
Brown 1979 [67] Toxic megacolon Patient had ulcerative colitis, used
LO for chronic diarrhoea. Dose/length
of use not specified.
von Muhlendahl 1980
[68]
Paralytic ileus 2 infants were treated with LO;
one-year-old with a single dose
(0.045 mg/kg), and a 17-month-old
with an overdose (1.4 mg/kg)
Chow 1986 [69] necrotising enterocolitis 2 infants were treated with LO, paralytic
ileus prior to necrotizing enterocolitis:
3-month-old had been treated with 0.4 mg/kg
for two days and a 7-month old 0.4 mg/kg for two days
Walley 1990 [70] Toxic megacolon LO 6 mg/day for 2 weeks. Clostridium
difficile was detected in the faeces only at
the diagnosis of toxic megacolon.
Olm 1991 [71] Two cases of necrotising enterocolitis with
perforation
Both patients had been treated with
LO 12 mg/day for 3 days
Epelde 1996 [72] Acute pancreatitis A case with LO overdose (24 mg)
Schneider 2000 [73] Toxic megacolon Toxic megacolon due to the use of loperamide
(dose not given) and Campylobacter infection.
The patient had bloody stools.
Eronen 2003 [74] Death LO (dose not reported) used in an epidemic
of gastroenteritis (later confirmed as
Bacillus spp). Toxic megacolon was
interpreted to be due to anticholinergic
effects of clozapine combined with LO.
Caumes 2004 [75] Case 1: necrotizing
colitis with perforation
Case 2: necrotising colitis
case 1: LO (dose not reported) 3 days
case2: LO 15 days
Perez-Calderon 2004
[76]
Anaphylaxis 2 mg tablet against acute gastroenteritis
Sklerov 2005 [77] Death Overdose of loperamide (dose not specified)
Srinivasa, 2007 [78] Death due to anaphylaxis Death due to anaphylaxis after ingestion of 2  2
tablets of LO
Kato 2007 [79] Toxic megacolon Patient had diarrhoea 3 weeks after
administration of broad-spectrum antibiotics,
eventually C. difficile was detected.
LO dose not reported
McGregor 2007 [80] Fulminant amoebic colitis Patient had used LO against TD
8 mg/day for 14 days
Lee 2011 [81] Acute pancreatitis Elevation of pancreatic enzymes after
overdose of loperamide (18 mg) and
trimebutine (600 mg)
Grondin 2012 [82] Shigella flexneri bacteremia Patient had used LO (dose not reported)
for bloody diarrhoea for five days
Vidarsdottir 2013 [83] Acute pancreatitis Used LO for 2 days: 10 mg on the first
day, 6 mg on the second
Di Rosa 2014 [84] Catatonia 12 mg of LO over 12 h (18 mg over 30 h).
Catatonia resolved with naloxone.
Dierksen 2015 [85] Death LO abuse, serum levels six times
peak therapeutic
Enakpene 2015 [86] Long QT and syncope Abuse of LO. Had probably taken
several bottles of LO.
Mancano 2015 [87] Cardiac arrhythmias 5 cases with cardiac arrhythmias after
overdose/abuse of LO 35-398 tablets
Spinner 2015 [88] Ventricular tachycardia LO 144 mg daily for two years
Labgaa 2015 [89] Recurrent acute pancreatitis Used LO 6 mg/day for 2 days; the first
episode was also preceded by the use of LO.
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nant amoebic colitis had used loperamide for two weeks
[80].
4. Discussion
Initially, loperamide was believed to have the same anti-
motility effect as diphenoxylate with atropin (Lomotil) and
similar agents. There is still a widespread conception that
the numerous adverse effects of these older antimotility
agents (e.g. toxic megacolon, pancreatitis, paralytic ileus,
anorexia, rash, itch) [91] also apply to loperamide. Later
studies have shown, however, that loperamide should not be
grouped together with these agents: in fact, given at lower
dosages, loperamide has minimal effect on motility, while
antimotility activity is only seen with larger doses [92].
The idea of using a drug like loperamide may be rejected
by travellers who prefer not to suppress diarrhoea which
they consider a part of our natural defence against intes-
tinal pathogens. This view is challenged by the current
perception that, rather than a host defence mechanism,
secretory diarrhoea is triggered and exploited by the
pathogen simply to facilitate transmission to new in-
dividuals [93]. This perception is nicely illustrated by
cholera, a disease where diarrhoea volumes may reach 20 L
per day, resulting in severe dehydration and even death of
the host. The same reasoning applies to enteroinvasive in-
fections: none of the steps in their pathogenesis appear
beneficial to the host defence system. There is a secretory
component even in this setting, but the most important
pathogenic mechanism seems to consist in causing direct
damage to the epithelium, leading to leakage and poor
uptake of water [92].
Current data suggest that loperamide has a potent
antisecretory effect even at low dosages [92], while higher
doses (above 12 mg) decrease motility [30,92]; this entails a
further increase in fluid absorption when the transit time is
prolonged, applying both to secretory and enteroinvasive
diarrhoea. However, at least in theory, higher dosage might
also prove harmful, for it may indicate a simultaneous in-
crease in exposure of the epithelium to microorganisms and
toxins. Taken together, the current literature suggests that
at moderate dosage, loperamide mostly has an anti-
secretory effect and bowel motility is not affected to the
same extent; no data implicate that the drug would be
unsafe.
4.1. Loperamide vs. antibiotics for TD
Interestingly, our literature search only yielded two ran-
domized trials [44,52] comparing loperamide and antibi-
otics in TD, neither of them with fluoroquinolones or
macrolides. In 1990, Ericsson et al. [44] found loperamide
used singly equal to cotrimoxazole. In the study by DuPont
et al. [52], loperamide was found inferior to rifaximin when
measured as TLUS, yet the mean number of loose stools on
day one was lower in the loperamide than the rifaximin
group. On day five there was no significant difference in the
“wellness achieved”.
In addition to the RCTs, we found a few observational
studies looking at the effectiveness of loperamide:antibiotics were not shown to be more effective than
loperamide in any of the observational studies either
[12,59,62,66]. Despite lacking proof of the superiority of
antibiotics, in some guidelines [14] they are recommended
as the primary treatment options. If there is no difference
in efficacy, adverse effects and other potentially harmful
long-term consequences should be weighed up. The dis-
cussion below will cover data on potential serious adverse
effects, focusing first on loperamide and then on antibi-
otics. It will also remark that during the last decade, the
sensitivity of diarrhoeal bacteria to empiric antibiotics has
been steadily decreasing.
4.2. Serious adverse effects of loperamide
Widely used by travellers against TD, loperamide has
proved effective and safe in both randomized trials and
observational studies (Tables 1e3), when taken according
to recommendations. Despite high fever or dysentery being
exclusion criteria for loperamide use in almost all ran-
domized studies, cases with invasive pathogens had been
found in most of them, if analysed. In nonrandomized
studies, loperamide had also been used by patients with
high fever or dysentery, yet only few reports specify the
proportion of such patients: in the study by Pitzurra et al.
[3], 21% used loperamide singly in dysentery.
Four case reports of severe cardiac arrhythmias con-
cerned patients with massive overdoses of loperamide. At
very high dosage, loperamide is able to cross the blood-
brain barrier and activate central opioid receptors, leading
to euphoria and analgesia, but also respiratory depression
and other opioid side effects [85]. Because of this, abuse of
loperamide is sometimes referred to as “poor man’s
methadone” [85,94].
In most of the case reports on serious adverse events
with loperamide (Table 4), the drug had been used against
recommendations: for diarrhoea resulting from use of
broad-spectrum antibiotics [70,79], for bloody diarrhoea
[72,82], to treat infants [68,69] or with intake lasting weeks
instead of days [70,75,80]. However, six of the case reports
comprised patients who had used loperamide according to
manufacturers’ recommendations [71,74,76,78,83,89], or
whose deviation from the guidelines was minimal [86].
4.3. Harmful effects of antibiotics
Although not common, the most frequently used TD anti-
biotics, fluoroquinolones and macrolides, are known to
potentially cause severe adverse effects, such as anaphy-
laxis [95,96], Stevens-Johnson’s syndrome [97,98], severe
dysglycaemia [99,100], and severe arrhythmias [101,102].
They are also known to predispose to C. difficile infections
[103].
Recent studies have shown antibiotic use in TD to in-
crease the risk of contracting multiresistant intestinal
bacteria, such as extended-spectrum beta-lactamase
-producing Enterobacteriaceae [21e23], and called for
caution in the use of antibiotics [104]. Indeed, in over 90%
of cases, the symptoms of TD are only mild or moderate
[2e4], and the disease resolves spontaneously. If drugs are
needed by these travellers, loperamide offers a safe
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severe diarrhoea. Even if their efficacy appears to increase
when taken together with loperamide [43], a recent study
suggests that combining the two may further increase the
risk of contracting multiresistant bacteria [27]. By contrast,
loperamide taken singly does not predispose to contracting
MDR bacteria [27].
4.4. Decreasing efficacy of antibiotics against
diarrhoeal pathogens
The potential efficacy of fluoroquinolones against TD in the
tropics, especially in Southeast Asia, is severely hampered
by increasing fluoroquinolone resistance among many
diarrhoeal bacteria, such as Campylobacter [105,106,109],
Salmonella [106,110,111], Shigella [106e108], ETEC
[112,113] and EAEC [112,113]. Likewise, the efficacy of the
alternative empiric antibiotic, azithromycin, is expected to
decrease: macrolide resistance has been documented
among Campylobacter spp. [106,109] and diarrhoeagenic E.
coli [113], for instance. The nonabsorbable alternative,
rifaximin, appears mostly ineffective against Campylo-
bacter but shows good in vitro activity against noninvasive
Enterobacteriaceae [106]. Besides decreased efficacy
against diarrhoeal pathogens, all the three antibiotics are
associated with “collateral damage” potentially leading to
selecting intestinal MDR bacteria of greater public health
concern [106].
5. Conclusion
The literature reviewed shows loperamide to be a safe and
effective agent for TD, but only if taken according to in-
structions. Racecadotril, another anti-secretory drug effec-
tive against diarrhoea, has not been studied with travellers.
To our surprise, the literature search only yielded
meagre data comparing loperamide alone to antibiotics; in
fact, adequate proof of antibiotics being more effective
than loperamide against TD was not found. Accordingly, in
light of the identified drawbacks of antibiotics, it seems
that they should be the drug of choice only for cases with
severe diarrhoea or underlying condition that might be
considerably deteriorated by TD.
In the present times, given the steadily growing anti-
microbial resistance, increasing likelihood of travellers
spreading the strains across the globe and importing them
to their home countries, and a clear pressure to restrict the
use of antibiotics during travel, loperamide may be a
valuable help to travellers needing relief from the annoy-
ance of diarrhoea while abroad.
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